Colin Barnes
VP of Intellectual Property
Colin has over 25 years experience working with global biotechnology companies. Colin was the first employee of DNA sequencing company Solexa (acquired by Illumina in 2007) and is an inventor on over 50 granted EP and US patents on the methodology as practised by Illumina.
Colin worked with Nuclera for several years as outside counsel, writing many of Nuclera’s patents, before joining in 2022 where he continues to work on drafting and prosecuting new IP.
In his spare time Colin enjoys playing bridge and watching rugby.
